MS treatment: Clinical trials due as human stem cells research shows promise

In fact, the process appeared more rapid and efficient than with other cell sources

The first clinical trials of a revolutionary approach to treating multiple sclerosis with stem cells derived from the patient’s own skin could begin soon following research showing that it works well on laboratory mice, scientists said.

A study has for the first time found that human skin cells converted into stem cells can be used to treat laboratory mice with a condition similar to multiple-sclerosis, where the fatty covering surrounding the nerves is lost.

Scientists in the US said initial clinical trials on human patients using a similar approach could begin in 2015, with full-scale studies soon after. The skin cells were first genetically engineered to become induced pluripotent stem cells (iPS) before being converted to the specialised cells that make the fatty myelin sheaths, which insulate nerve cells in a similar way to the plastic covering of an electrical wire. The myelin is gradually degraded in MS patients.

Scientists were able to turn the iPS cells into oligodendrocyte progenitor cells which were injected into the mice. These progenitor cells went on to become fully specialised oligodendrocytes, the cells responsible for making the myelin sheath.

“The new population of oligodendrocyte progenitor cells and oligodendrocytes was dense, abundant and complete. In fact, they re-myelination process appeared more rapid and efficient than with other cell sources,” said neurologist Steven Goldman of Rochester University Medical Centre in New York. Induced pluripotent stem cells are created by adding several genes to ordinary skin cells. This has the effect of “reprogramming” them back to an earlier, embryonic-like state, but has the ethical advantage over true embyronic stem cells in that they do not require the creation of human embryos.

 Clinical trials of human induced pluripotent stem cells on MS patients are being funded by an organisation called New York State Stem Cell Science, which has already approved initial trials using stem cells, which are due to begin within two years.

PROMOTED VIDEO
News
ebooksNow available in paperback
Latest stories from i100
Have you tried new the Independent Digital Edition apps?
Independent Dating
and  

By clicking 'Search' you
are agreeing to our
Terms of Use.

iJobs Job Widget
iJobs General

Reach Volunteering: Financial Trustee and Company Secretary

Voluntary Only - Expenses Reimbursed: Reach Volunteering: A trustee (company d...

Recruitment Genius: Senior Project Manager

£45000 - £65000 per annum: Recruitment Genius: This is a fantastic opportunity...

Recruitment Genius: Shopfitter

Negotiable: Recruitment Genius: This is an opportunity to join a successful an...

Recruitment Genius: Digital Sales Account Manager

£25000 - £30000 per annum: Recruitment Genius: A Digital Sales Account Manager...

Day In a Page

Mau Mau uprising: Kenyans still waiting for justice join class action over Britain's role in the emergency

Kenyans still waiting for justice over Mau Mau uprising

Thousands join class action over Britain's role in the emergency
Isis in Iraq: The trauma of the last six months has overwhelmed the remaining Christians in the country

The last Christians in Iraq

After 2,000 years, a community will try anything – including pretending to convert to Islam – to avoid losing everything, says Patrick Cockburn
Black Friday: Helpful discounts for Christmas shoppers, or cynical marketing by desperate retailers?

Helpful discounts for Christmas shoppers, or cynical marketing by desperate retailers?

Britain braced for Black Friday
Bill Cosby's persona goes from America's dad to date-rape drugs

From America's dad to date-rape drugs

Stories of Bill Cosby's alleged sexual assaults may have circulated widely in Hollywood, but they came as a shock to fans, says Rupert Cornwell
Clare Balding: 'Women's sport is kicking off at last'

Clare Balding: 'Women's sport is kicking off at last'

As fans flock to see England women's Wembley debut against Germany, the TV presenter on an exciting 'sea change'
Oh come, all ye multi-faithful: The Christmas jumper is in fashion, but should you wear your religion on your sleeve?

Oh come, all ye multi-faithful

The Christmas jumper is in fashion, but should you wear your religion on your sleeve?
Dr Charles Heatley: The GP off to do battle in the war against Ebola

The GP off to do battle in the war against Ebola

Dr Charles Heatley on joining the NHS volunteers' team bound for Sierra Leone
Flogging vlogging: First video bloggers conquered YouTube. Now they want us to buy their books

Flogging vlogging

First video bloggers conquered YouTube. Now they want us to buy their books
Saturday Night Live vs The Daily Show: US channels wage comedy star wars

Saturday Night Live vs The Daily Show

US channels wage comedy star wars
When is a wine made in Piedmont not a Piemonte wine? When EU rules make Italian vineyards invisible

When is a wine made in Piedmont not a Piemonte wine?

When EU rules make Italian vineyards invisible
Look what's mushrooming now! Meat-free recipes and food scandals help one growing sector

Look what's mushrooming now!

Meat-free recipes and food scandals help one growing sector
Neil Findlay is more a pink shrimp than a red firebrand

More a pink shrimp than a red firebrand

The vilification of the potential Scottish Labour leader Neil Findlay shows how one-note politics is today, says DJ Taylor
Bill Granger recipes: Tenderstem broccoli omelette; Fried eggs with Mexican-style tomato and chilli sauce; Pan-fried cavolo nero with soft-boiled egg

Oeuf quake

Bill Granger's cracking egg recipes
Terry Venables: Wayne Rooney is roaring again and the world knows that England are back

Terry Venables column

Wayne Rooney is roaring again and the world knows that England are back
Michael Calvin: Abject leadership is allowing football’s age-old sores to fester

Abject leadership is allowing football’s age-old sores to fester

Those at the top are allowing the same issues to go unchallenged, says Michael Calvin